US pharmaceutical giant Pfizer has announced its coronavirus vaccine candidate was more than 90 percent effective in preventing COVID-19, based on the results of the latest trials.

“Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis”, the company said in a press release.

According to the press release, the “mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on 8 November 2020 by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical study”.

Pfizer announced that it expected to produce up to 50 million doses of its coronavirus vaccine in 2020 and up to 1.3 billion doses in 2021.

The number of people diagnosed with coronavirus has surpassed 50 million worldwide, while the global death toll is over 1,250,000.